NIH R01 · 2024
In Vivo Oncogene-Induced Tumorigenesis and Escape
Recurrent breast cancer is typically an incurable disease. Consequently, the tendency of breast cancers to recur following treatment is the most important determinant of clinical outcome. Recurrent tumors arise from the reservoir of residual tumor cells (RTCs) that can persist in patients in a presumed dormant state for decades after treatment of their primary tumor. As such, minimal residual disease, tumor dormancy, and recurrence constitute fundamental manifestations of tumor progression that collectively are responsible for the vast majority of breast cancer deaths. Despite their unrivaled clinical importance, however, the mechanisms underlying them are largely unknown. Consequently,…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.